Inventiva Says Lanifibranor 800mg Achieved The Primary Efficacy Endpoint
Portfolio Pulse from Benzinga Newsdesk
Inventiva announced that Lanifibranor 800mg achieved the primary efficacy endpoint in a Phase II clinical trial, showing a 44% reduction of Intra Hepatic Triglycerides in patients with NAFLD and T2D. This result is consistent with the Phase IIb NATIVE trial findings.
June 13, 2023 | 9:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inventiva's Lanifibranor 800mg achieved the primary efficacy endpoint in a Phase II clinical trial, indicating potential success in treating NAFLD and T2D patients.
The positive results from the Phase II clinical trial indicate that Lanifibranor 800mg is effective in treating NAFLD and T2D patients. This achievement is likely to have a positive impact on Inventiva's stock price in the short term, as it demonstrates the potential success of the drug and its ability to generate revenue for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100